Healthcare Industry News: Fresenius Kabi Pharmaceuticals
News Release - June 29, 2010
APP Pharmaceuticals to Market Anastrozole Tablets in the U.S.SCHAUMBURG, Ill.--(HSMN NewsFeed)--Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ ) announced today that APP Pharmaceuticals will immediately begin marketing Anastrozole tablets in the U.S., after the U.S. Food and Drug Administration granted approval to market the breast cancer treatment medication to Fresenius Kabi Oncology Limited (NSE:FKONCO) (BSE:532545 ). APP Pharmaceuticals and Fresenius Kabi Oncology Limited are members of the Fresenius Kabi Group of companies. Anastrozole is therapeutically equivalent to the reference-listed drug Arimidex®, which is currently marketed by the innovator AstraZeneca.
APP will market Anastrozole in 1 mg tablets. According to IMS data, 2009 sales of the branded product in the United States were approximately $916.8 million, with approximately 105 million tablets sold annually.
“The approval of Anastrozole further expands APP's product portfolio in the strategically important Oncology segment,” said John Ducker, president and chief executive officer of APP Pharmaceuticals. “We are delighted to be able to offer this important oral medication to new customers in the retail pharmacy channel.”
Anastrozole is approved for the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer. It is also a first-line treatment for postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer. In addition, Anastrozole is used in the treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with estrogen receptor-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to Anastrozole.
About APP Pharmaceuticals, Inc.
APP Pharmaceuticals, Inc. is a fully-integrated pharmaceutical company that develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. The company offers one of the most comprehensive product portfolios used in hospitals, long-term care facilities, alternate care sites and clinics within North America and manufactures a comprehensive range of dosage formulations. Fresenius Kabi Pharmaceuticals Holding, Inc., a wholly owned subsidiary of Fresenius Kabi AG, acquired APP Pharmaceuticals, Inc. on September 10, 2008. For more information about APP Pharmaceuticals, Inc., please visit the company’s Web site at www.APPpharma.com.
Fresenius Kabi Oncology Limited
Fresenius Kabi Oncology Limited is one of the leading companies for cancer research and anti-cancer products. Leveraging the global outreach through integration with Fresenius Kabi, Fresenius Kabi Oncology Limited is benchmarking oncology excellence with world class production, state-of-the-art manufacturing and research & development facilities. Fresenius Kabi Oncology Limited has world class expertise for the development and manufacturing of active pharmaceutical ingredients, intermediates and oral & injectable finished dosage forms.
About Fresenius Kabi AG
Fresenius Kabi AG is the leader in infusion therapy and clinical nutrition in Europe and in its most important countries of Latin America and Asia Pacific. Fresenius Kabi’s core product range includes infusion solutions, blood volume substitutes, I.V. drugs and parenteral nutrition, as well as products for enteral nutrition. Furthermore, the company provides concepts for ambulatory health care and is focused on managing and providing home therapies. With the philosophy “caring for life” and a comprehensive product portfolio, the company aims at improving the quality of life of critically and chronically ill patients all over the world. In 2009, Fresenius Kabi achieved sales of EUR 3,086 million and an operating profit of EUR 607 million. For more information visit the company’s Web site at www.fresenius-kabi.com. Fresenius Kabi AG is a 100% subsidiary of Fresenius SE.
The statements contained in this news release that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this news release include statements regarding our expectations, beliefs, hopes, goals, intentions, initiatives or strategies, including statements regarding the demand, supply and distribution of our products. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those in the forward-looking statements. Additional relevant information concerning risks are discussed under the headings “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Fresenius Kabi Pharmaceuticals Holding, Inc. 10-K for the fiscal year ending December 31, 2009 and other documents the company has filed with the Securities and Exchange Commission.
The information contained in this news release is as of the date of this release. Fresenius Kabi Pharmaceuticals Holding, Inc. does not assume any obligation to update or revise these forward-looking statements to conform the statement to actual results, new information, developments or changes in the Company’s expectations.
1 2009 IMS Data
Arimidex® is a registered trademark of AstraZeneca.
Source: APP Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.